Hospital-Treated Gram-Negative Infections | Disease Landscape & Forecast | G7 | 2022
The rising rates of antimicrobial resistance (AMR) have created an emergent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Since the emergence of the COVID-19 pandemic, a potential public health threat of antibiotic-resistant bacteria is now becoming increasingly urgent. Antibiotics such as carbapenems, which have historically been reserved for later lines of therapy, are being used earlier in treatment, placing additional pressure on the already-limited GNI armamentarium. Despite the launch of novel antibiotics, such as AbbVie / Pfizer’s Avycaz / Zavicefta, Merck & Co.’s Zerbaxa and Recarbrio, and Shionogi’s Fetroja / Fetcroja, unmet need remains for additional treatment options with novel mechanisms of action and with efficacy in patients with drug-resistant infections, which are associated with high rates of mortality. Although the market is heavily genericized and cost-containment measures have limited commercial success of emerging therapies, innovative market push and pull approaches such as value-based pricing (VBP) and de-linked drug reimbursement models promise to encourage and support future antibiotics development.
QUESTIONS ANSWERED
- How large are the treatable HABP / VABP / HCAP, cSSSI / SSI, cIAI, BSI, and UTI populations? What are the resistance rates to different classes of antibiotics across several pathogen species?
- What is the state of treatment for hospital-treated GNIs? What are the most important drugs, and why? What clinical needs remain unfulfilled?
- What impact will the emerging antibiotic therapies have on the GNI therapy market? Which emerging therapies generate the most enthusiasm among thought leaders? How will ID specialists in different markets make treatment decisions among the emerging therapies in the future?
- On what attributes will pipeline therapies need to improve in order to compete with currently marketed products?
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan
Primary research: 20 country-specific interviews with thought-leading infectious disease specialists. Supported by survey data collected for this and other Clarivate research
Epidemiology: Diagnosed cases of GNIs by country, segmented by key infections (HABP / VABP/ HCAP, CSSSI / SSI, cIAI, BSI, and UTI), pathogens (E. coli, Pseudomonas, Acinetobacter, Klebsiella), and resistance types
Forecast: 10-year, annualized, drug-level sales and patient share of key GNI therapies through 2031, segmented by brands / generics, geography, and five key infection types
Emerging therapies: Phase III/PR: 8 drugs; Phase I/Phase II: 10 drugs
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
